Free Trial Information
BioCentury | Apr 25, 2019
Politics & Policy

RAC reborn as NExTRAC to advise NIH on safety, ethics of emerging technologies

...a germline editing experiment in twin girls in China (see "The Other Side of the Rubicon"...
Read More
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

...at mosaicism. The embryos were destroyed after three days (see “The Other Side of the Rubicon”...
Read More
BioCentury | Dec 1, 2018
Politics, Policy & Law

China’s germline growing pain

...without more extensive testing on other mutations and embryos (see “The Other Side of the Rubicon”...
Read More
BioCentury | Oct 12, 2018
Preclinical News

Gene editing creates offspring from same-sex parents

...embryos that are not intended to create live births (see "The Other Side of the Rubicon...
Read More
BioCentury | Aug 22, 2018
Translation in Brief

Confirming CRISPR

...where to start and how to do it safely (see “The Other Side of the Rubicon”...
Read More
BioCentury | Sep 27, 2017
Translation in Brief

Editing without translation

...human embryos were modified by CRISPR in the U.S. (see "The Other Side of the Rubicon."...
Read More
BioCentury | Aug 9, 2017
Distillery Techniques

Drug platforms

...include increasing targeting efficiency of CRISPR-Cas9 constructs in embryos (see "The Other Side of the Rubicon."...
Read More
BioCentury | Aug 3, 2017
Tools & Techniques

The other side of the Rubicon

In the end, it might be the efficacy that guides the ethics. By showing that editing of human embryos using CRISPR can be performed efficiently and without leading to the much-feared slew of off-target cuts,...
Read More
BioCentury | Mar 17, 2014
Regulation

Slippery slope

...is whether the biotech will be able to reach a reimbursement deal without crossing that Rubicon...
Read More
BioCentury | Feb 17, 2014
Company News

Illumina, Rubicon sales and marketing update

...of other single-cell samples, such as circulating tumor cells. Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Rubicon Genomics Inc....
Read More
Items per page:
1 - 10 of 36
BioCentury | Apr 25, 2019
Politics & Policy

RAC reborn as NExTRAC to advise NIH on safety, ethics of emerging technologies

...a germline editing experiment in twin girls in China (see "The Other Side of the Rubicon"...
Read More
BioCentury | Mar 19, 2019
Regulation

Talk less, do more: Germline gene editing needs real plans, not just moratoria

...at mosaicism. The embryos were destroyed after three days (see “The Other Side of the Rubicon”...
Read More
BioCentury | Dec 1, 2018
Politics, Policy & Law

China’s germline growing pain

...without more extensive testing on other mutations and embryos (see “The Other Side of the Rubicon”...
Read More
BioCentury | Oct 12, 2018
Preclinical News

Gene editing creates offspring from same-sex parents

...embryos that are not intended to create live births (see "The Other Side of the Rubicon...
Read More
BioCentury | Aug 22, 2018
Translation in Brief

Confirming CRISPR

...where to start and how to do it safely (see “The Other Side of the Rubicon”...
Read More
BioCentury | Sep 27, 2017
Translation in Brief

Editing without translation

...human embryos were modified by CRISPR in the U.S. (see "The Other Side of the Rubicon."...
Read More
BioCentury | Aug 9, 2017
Distillery Techniques

Drug platforms

...include increasing targeting efficiency of CRISPR-Cas9 constructs in embryos (see "The Other Side of the Rubicon."...
Read More
BioCentury | Aug 3, 2017
Tools & Techniques

The other side of the Rubicon

In the end, it might be the efficacy that guides the ethics. By showing that editing of human embryos using CRISPR can be performed efficiently and without leading to the much-feared slew of off-target cuts,...
Read More
BioCentury | Mar 17, 2014
Regulation

Slippery slope

...is whether the biotech will be able to reach a reimbursement deal without crossing that Rubicon...
Read More
BioCentury | Feb 17, 2014
Company News

Illumina, Rubicon sales and marketing update

...of other single-cell samples, such as circulating tumor cells. Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Rubicon Genomics Inc....
Read More
Items per page:
1 - 10 of 36